A life in science - with Elizabeth Blackburn

nature video
11 followers
1 Video View·Sep 5, 2023
Elizabeth Blackburn grew up in Hobart on the Australian island of Tasmania. It was a long journey from there to a Nobel prize and the lab she runs at the University of California in San Francisco. Malaria researcher Clare Smith is also a Hobart girl, and she's trying to decide whether to follow in Blackburn's footsteps and move overseas after she finishes her PhD. Karina Zillner is from Germany. Like Clare, she's in the final stages of a PhD. She's developed a method for analysing sections of repetitive DNA. Karina hopes her technique might be used in Blackburn's lab, where they study telomeres — repetitive sections of DNA that protect the ends of chromosomes.
Elizabeth Blackburn won the Nobel Prize for her discoveries at the molecular level of
how the ends of chromosomes, the so-called telomeres, work.
It's a fundamental mechanism.
So this week in the Dow I'd love to meet Elizabeth Blackburn.
She's a Hobart girl like me, both come from the same small town in Australia, and she's
gone on to pretty great things.
The ends of the chromosomes consist of a special DNA sequence that is repeated many,
many times.
The enzyme telomerase, which makes the ends of the chromosomes, is really important because
if you have not enough telomerase, the cells stop dividing.
And this is basically what you call ageing.
When you have too much of it, the DNA is not stable anymore, and that causes cancer.
And that's why telomeres are so important.
So where are you from, and tell me all about where, did you come from different parts of
the world?
I'm from the University of Regensburg, and I'm interested in DNA methylation and repetitive
sequences.
Oh great.
And what about you?
Yes, I'm actually, I've come from Hobart.
No way!
I know.
You still live there?
Yes.
I'm just about to submit my PhD.
Oh terrific, terrific.
Yeah, on some malaria research, so looking at host susceptibility, so it's a new type
of quite different therapies.
Yes, yes.
So yeah, about to submit, and then come over and work at Pasteur.
Oh good.
I arrived on Saturday, and already two hours later, I was discussing with different parts
of the world about science and also history.
What makes me sad is when people get very protective about their results, and they won't
talk about it until it's published, right?
So I've just decided, I spill the beans, and basically I talk, and I don't think there's
ever been a time when it was, you know, a mistake to have done that.
But as students, we want to go and, you know, just share and tell, and then there's other
people going, no, no, you've got to wait and hang on.
I know.
My feeling was that's probably a mistake in the long run, and probably even in the middle
run as well, and it might seem as though, oh, somebody sort of took my idea, but in
fact it never really happens either, you know.
They might publish something similar, and maybe they publish it first and messier, right?
But you publish, and that, in the end, it prevails.
And I think it's well worth it to talk.
Science now is this industrial-driven, application-driven, maybe also hypothesis-forced, that you have
to do the experiment again and again until you get the expected result.
Isn't that awful?
Yes, yes.
And that is just terrible.
I know.
But my take on it is what happened was that I think there was a lot of really ghastly
clinical research that was being done, right?
It was really awful stuff.
And so then people started to say, look, you have to have a hypothesis, and you have to
do it.
And so then the clinical things started to get sort of formulated.
Here's my hypothesis, and my job is to prove it.
No.
In science, your job is to see if you can disprove the hypothesis.
That's real science.
But as you say, it got sort of distorted into this, here's my idea, and now I'm going to
do everything I can to make my data fit this, which is so distorting.
But I think there's also a problem with grant writing, because when you apply for funding,
you already have to, you know, have this plan for the next year, let's see in Germany.
Let's get this clear about grants.
I mean, I have a very clear idea.
There's two worlds.
There's called science, and there's called grants, okay?
They coexist.
They are not the same.
And the biggest mistake is to mistake the two for the, one for the other.
You can't sit and write a grant application and say, well, I think I might find a new
enzyme.
Doesn't go down well with the review sections, okay?
But you can have wonderful funding which opens up the possibility, which says, let's look
at how telomeres work.
And I'm so grateful to a funding agency like the NIH that said, you have a grant that's
called Structure and Function of Telomeres, and within that, I could run with the question.
The person who used to run all the grants from the NIH, he once said, what's happened
is that people start mistaking the specific aims for the science.
And he said, we all understood that you take the money and run, okay?
That's the idea.
You take the money, and you run with the science.
And he said, the tragedy now is that study sections now, you know, they got very sort
of picky and said, oh, they didn't do their specific aims.
But the whole point was, nobody's ever penalized for going and doing something interesting
and not finishing all their specific aims.
When somebody comes to you with a really interesting question that just grabs you, and you think
that person is good at that kind of research, go for it.
So we started a collaboration.
And this was wonderful because our friends in the UCSF Department of Psychiatry were
very interested in chronic stress.
And we found, lo and behold, that we could interact and show then people, in which chronic
stress, by the way, is a known risk factor for common diseases, such as cardiovascular,
that telomere shortness was associated with chronic stress.
When I started collaborating with Alyssa, who's working with people who are in really
awfully hard situations, right, you know, mothers of chronically ill children, caregivers
of, you know, their husband or, you know, partner or somebody who has dementia, I mean,
these people are under major long-term stress.
The patients are being looked after and the caregivers are being ignored.
During my PhD thesis, I developed a method which enables the analysis if genes are switched
on or if they are switched off.
The great advantage of this method is that it works on repetitive DNA, such as telomeres.
We had this question that we want to answer, but there was no method to use.
It was kind of risky because I established a new method.
What was the method?
What was it about?
We call it epicombing, and it's about DNA methylation at repetitive sequences.
And with the methods that are established so far, you can't look for DNA methylation
patterns, so at individual repeats next to each other if they are epigenetically linked.
On the same molecule.
Exactly.
So you're using combing to...
Yeah, exactly.
So do you know the method combing?
Sure, yes.
What was the epi part then?
Before doing the fish, we do an immunofluorescence with specific antibodies against DNA methylation
and also against DNA hydroxymethylation.
Got it.
Terrific.
So you're combing the hydroxymethyl Cs and the 5-methyl Cs.
Exactly.
Her recent research showed that environmental factors such as stress shorten telomeres.
And other studies showed that environmental factors are able to switch genes off and on.
So therefore, I hope that she can use my method to analyze if genes around the telomeres can
be switched off or on by environmental factors.
I would love to do that with this chronic stress.
Yes.
If the link of these environmental factors might be DNA methylation at some telomeres.
I would love to do that, yes.
Because there are other studies that already show that DNA methylation plays an important
role in stress development.
Yes.
And your method might be even more important because people have been looking at DNA methylation
in the sub-telomeric regions.
There was a meeting recently and they looked at some of the mutants in people who have
very short telomeres and so on.
The answer was extremely confusing, okay, but of course they weren't using your method.
With the normal methods, you measure an average of presence of cells, the average of all chromosomes
and the average of individual repeats on a chromosome.
So what you measure is just an average.
You miss the pattern.
You'll miss the pattern of methylation and the pattern may be the key.
Yes.
Exactly.
I'm sure Elizabeth Blackburn didn't hear about the method I developed before because it's
not published yet and I'm sure she can use it in her lab.
So while I'm working on malaria research, which is an eternity away from telomeres and
what Elizabeth does, what I'm looking to Elizabeth for is the same idea we're both cell biologists.
We both started with cell biology and with malaria research, we take it through and try
and translate it and that's kind of what Elizabeth's done.
She's taken some basic cell biology and taking it through to the clinic.
We didn't hear what you were doing, malaria, but you said there's interesting new avenues for therapy.
Yes.
Well, instead of targeting the parasite, it mutates and overcomes it so quickly.
What about the host factors?
The parasite steals host factors.
Yes.
So as an honours student, I was thrown this crazy idea.
Clegg, we've got a host-directed therapy.
Good.
Off you go.
It was a little bit, ooh.
Everyone's like, don't do that project and come to the end.
When they say don't do it, then you think, that sounds like a good one.
Yes, exactly.
So I've identified these factors and we've found some drugs and now we've got it through from the cells to the mice into the people.
So that's what I'm going to pass dirt to you.
I grow up the parasites and I try and kill them with these new drugs.
And so as a student, being able to take it through and now looking towards the clinic and how this is applied in people
and getting it to the people that need it, it's an exciting thing.
But I think the other interesting thing is, when do you start collaborating in terms of, do you do it early in your career?
Do you do it late?
I mean, I didn't do any of the clinical stuff until the late 1990s.
And I think you really have to become very, you have to be able to bring something to the table.
Your expertise, I think you want to develop a deep expertise.
So I do it in phases.
So I was very, very hardworking, early sort of phases.
And then I got pregnant.
And so, OK, so now our son was born.
And so, of course, now the science got complicated because now you had to be much more scheduled.
You just had to organize it differently.
And it's crazy to lose a scientist because of a few years of when there's intensive need for having children.
It seems crazy.
You throw away a scientist because that person is going to be busy with family for just a few years.
And then you've thrown away them being a scientist for the rest of their lives.
It doesn't make sense.
No.
It was amazing.
Yeah.
It was such a great experience.
Yeah.
She's all about sharing the ideas rather than keeping science secret.
So much in science now, everyone hides what they do before they publish it.
She doesn't think like that at all.
It's really refreshing to hear a scientist that says, I don't care.
I'm going to share this and let's get the new knowledge out there.
Yeah.
She instantly realizes the impact of my established method that she really liked it and said that it will answer so many unresolved questions.
So even though I don't necessarily work on epigenetics, a wider genetics group back in Hobart, we're doing kind of similar stuff.
And Corinna's new technique would be very useful.
So maybe Corinna should come to Australia.
Yeah.
I'd love to establish it in Tasmania and, you know, educate and inspire and connect.
That's what it's all about.
Well, I think Claire and Corinna are clearly terrific.
You know, they have success written all over them.
And they've already done research in which they've really taken the initiative.
The kind of attitude they've had is what's going to bring them success in the future.
